Treatment of Hereditary Angioedema "Notification"
New policy developed to address the FDA approved products used as treatment of Hereditary Angioedema. BCBSNC will provide coverage for Cinryze®, Berinert®, Kalbitor® (Ecallantide), and Firazyr® (Icatibant) when it is determined to be medically necessary because the medical criteria and guidelines are met. Medical Director review 6/2012. Notification given 6/29/12 for effective date 10/01/12.
Laryngeal Hereditary Angioedema added as a clinical indication for treatment with Berinert®. Policy remains on 90 day notification with effective date 10/01/2012.